Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.07, $0.11 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $94.52 million versus the consensus estimate of $87.77 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.